This study is arandomized, double-blind, placebo-controlled study that will evaluate thesafety and efficacy of dasiglucagon in children between the ages of 7 days and12 months who have congenital hyperinsulinism. Dasiglucagon will be given as asubcutaneous infusion while patients are admitted to the hospital. Othertreatments for hyperinsulinism may be changed as allowed while maintaining safeblood sugar levels. For the second part of the study, patients may be able togo home on the medication.
For More InformationContact Us Online
Call (267) 426-6846